Paper - WANFANG MED ONLINE

You Position: Home > Paper

Application of Irinotecan in locally advanced or metastatic esophageal carcinoma

( views:71, downloads:140 )

Author:: No author available

Journal Title:: CANCER RESEARCH AND CLINIC

Issue:: 5

DOI:: 10.3760/cma.j.issn.1006-9801.2010.05.002

Key Word:: 食管肿瘤;伊立替康;顺铂;多西紫杉醇;放射疗法;计算机辅助;Esophageal neoplasms;Irinotecan;Cisplatin;Docetaxel;Radiotherapy,computerassisted

Abstract： Esophageal carcinoma represents high incidence and mortality rate in China.Irinotecan (CPT-11) has shown promising activity in a number of gastrointestinal cancers,including esophageal cancer.This article reviews recent clinical trials of irinotecan-based chemotherapy and radiochemotherapy in esophageal carcinoma.

Reference

[1]Peter C, Enzinger,Robert J, Mayer.Esophageal cancer.[J].2003,349(23).
[2]Lee JS,Kim HY,Lee DH,etc.A phase II trial of modified weekly irinotecan and cisplatin for chemotherapy-naive patients with metastatic or recurrent squamous cell carcinoma of the esophagus.[J].2008,61(1).
[3]Boxberger F,Reulbach U,Ostermeier N,etc.Weekly high-dose 5-fluorouracil as a 24-h infusion and sodium folinic acid (AIO regimen) plus irinotecan in patients with locally advanced nonresectable and metastatic adenocarcinoma or squamous cell carcinoma of the oesophagus: a phase II trial.[J].2009,20(3).
[4]Riecken EO,Scherubl H,Ohnesorge I,etc.A pilot study of irinotecan (CPT-11) as single-agent therapy in patients with locally advanced or metastatic esophageal carcinoma.[J].2003,18(4).
[5]Schaaf LJ,Kemeny N,Schwartz GK,etc.Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors.[J].1998,16(12).
[6]Yasuhiko Kano,Miyuki Akutsu,Saburo Tsunoda,etc.In vitro schedule-dependent interaction between paclitaxel and SN-38 (the active metabolite of irinotecan) in human carcinoma cell lines[J].1998,42(2).
[7]Gibson M,Egleston B,Burtness B.Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer.[J].2009,20(7).
[8]Von Schilling C,Lordick F,Bernhard H,etc.Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer.[J].2003,89(4).
[9]Bokemeyer C,Teichmann R,Burkart C,etc.A phase II trial of weekly irinotecan in cisplatin-refractory esophageal cancer.[J].2007,27(4C).
[10]Y, Kano,K, Suzuki,M, Akutsu,etc.Effects of CPT-11 in combination with other anti-cancer agents in culture.[J].1992,50.
[11]Kawase I,Fukuoka M,Yamakido M,etc.Enhancement of tumor radio-response by irinotecan in human lung tumor xenografts.[J].1997,88(2).
[12]O'Reilly E,Huang Y,Kornblith A,etc.Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer.[J].1999,17(10).
[13]P C, Enzinger,D H, Ilson,D P, Kelsen.Chemotherapy in esophageal cancer.[J].1999,26.
[14]Adenis A,Michel P,Di Fiore F,etc.Induction cisplatin-irinotecan followed by concurrent cisplatin-irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trial.[J].2006,95(6).
[15]Rudin CM,Vokes EE,Das S,etc.Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.[J].2004,22(8).
[16]Rosenthal SethA,Kelsen DavidP,Minsky BruceD,etc.INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy.[J].2002,20(5).
[17]Nagai K,Kawano T,Miyake S,etc.CPT-11 may provide therapeutic efficacy for esophageal squamous cell cancer and the effects correlate with the level of DNA topoisomerase I protein.[J].2001,92(12).
[18]X H, Pei,Y, Nakanishi,K, Takayama,etc.Effect of CPT-11 in combination with other anticancer agents in lung cancer cells.[J].1997,8.
[19]Tanaka K,Nishikage T,Toukairin Y,etc.The expressions of p21 and pRB may be good indicators for the sensitivity of esophageal squamous cell cancers to CPT-11: Cell proliferation activity correlates with the effect of CPT-11.[J].2004,95(5).